Halozyme Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Halozyme Therapeutics, Inc.
Towa’s US-based Breckenridge is aiming for exclusivity with its generic version of Amgen’s Kyprolis – developed with partner Natco Pharma – after obtaining one of the first approvals for several strengths of the treatment for relapsed or refractory multiple myeloma.
Brazil is permitting imports of additional coronavirus vaccines, while in India, Serum Institute will manufacture Sputnik V, the government is unifying vaccine sourcing, and emergency use approval has been granted to Lilly's anti-COVID-19 antibodies.
Antiviral favipiravir brings stunning gains to Glenmark, almost equal to the entire India sales of some multinationals, as demand surged amid the ferocious second of COVID-19 in the country. Such brand build-up could have taken five to seven years in pre-pandemic times, experts said.
Lilly brings challenger Natco into licensee fold for baricitinib in COVID-19, while the Indian firm retracts a compulsory licensing application for the JAK inhibitor, rapidly diffusing a potentially difficult situation for both sides. But will the six other baricitinib licensees in India match the price of Natco’s on-market version?
- Drug Delivery
- Drug Discovery Tools